Core Insights - Genenta Science has provided an update on its TEM-GBM study for newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter, reporting that 25 patients have been treated with Temferon as of November 21, 2025 [1][2] Group 1: Clinical Study Results - Key survival metrics for TEM-GBM patients show that 44% of patients have reached 18-month survival, an increase from 38% reported in April 2025 [7] - The two-year survival rate remains at 29%, and the median overall survival is consistent at 17 months, compared to historical cohorts of uMGMT patients treated with standard care, which typically show a two-year survival rate of approximately 14% and median overall survival of 13-15 months [7] - The study includes a patient who has reached three years of survival following Temferon administration, marking a significant milestone in the study [7] Group 2: Mechanism and Observations - The GBM study provides early observations on Temferon's behavior within the tumor microenvironment, indicating that bone-marrow-derived myeloid cells can deliver immunotherapeutic payloads at the tumor site, aligning with the platform's intended design [3] - These preliminary findings are exploratory and will inform the broader development of Temferon, including potential combination approaches and the evolution of the underlying cell-based delivery technology [3] Group 3: Financial Position - Following a registered direct offering on October 27, the company reported approximately $30 million in cash and short-term investments as of November 1, 2025 [4] Group 4: Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for various solid tumor cancers, with Temferon as its first-in-class product candidate [5] - The company has completed a Phase 1 trial for newly diagnosed GBM patients with an unmethylated MGMT gene promoter, suggesting potential reprogramming of the tumor microenvironment and induction of T cell responses [5] - Genenta has also initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has strategic partnerships with industry leaders, enhancing its research and development capabilities [1] Price Target Changes - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00, indicating a shift in analyst sentiment [2][5] - This decline in price target suggests potential influences from recent developments or broader market conditions affecting the biotech sector [2] Investment Considerations - Investors should monitor NovaBridge's ongoing clinical trials and strategic partnerships, as these factors could significantly impact future performance and stock valuation [3][5] - New announcements or updates from NovaBridge may provide further insights into potential stock movements [3] Comparative Analysis - In contrast, IMab has received a positive outlook from analysts, with a price target set at $8, reflecting increased optimism about its earnings prospects [4] - This comparison highlights the importance of analyst ratings and price targets in assessing biotech stocks [4][5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has established strategic partnerships with major players in the industry to enhance its research and development efforts [1] Price Target Analysis - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past month, indicating a more cautious short-term outlook from analysts [2][5] - Despite the recent decrease, the price target has remained stable over the past year, suggesting a consistent long-term view of the company's potential [2] Comparative Analysis with IMab - IMab has been upgraded to a Zacks Rank 2 (Buy), with a new price target of $8 set by analyst Kumaraguru Raja, reflecting increased optimism about its earnings potential [3][5] - The contrasting outlooks for NovaBridge and IMab highlight varied analyst sentiments based on recent developments in the biotech sector [4][5]

FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced it has executed a 4-month extension of its collaboration with The Scripps Research Institute ("Scripps Research") and the lab of Dr. Alexey Stepanov, Institute Investigator at Scripps Research effective November 1, 2025, to advance the develop ...

Core Insights - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment and improving patient survival [1][3] - The company will participate in two significant healthcare conferences: the Jefferies Global Healthcare Conference in London and the Piper Sandler 37th Annual Global Healthcare Conference in New York [1][2] Conference Details - Jefferies Global Healthcare Conference: - Format: Fireside Chat - Date: November 19, 2025 - Time: 11:30 AM GMT / 6:30 AM EST - Location: London, UK [2] - Piper Sandler 37th Annual Global Healthcare Conference: - Format: Fireside Chat - Date: December 3, 2025 - Time: 9:30 AM EST - Location: New York, NY [2] Company Pipeline - ALX Oncology's lead candidate, evorpacept, is positioned as a potential cornerstone therapy in immuno-oncology and is undergoing multiple clinical trials across various cancer indications [3] - The second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate that began Phase 1 trials in August 2025 [3]

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassion ...

Summary of Regeneron Pharmaceuticals Conference Call Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Date of Conference**: November 17, 2025 - **Key Speakers**: Justin Holco (Global Oncology Hematology Commercial Business Unit Lead), Izzy Lowy (Clinical Development Unit Head), Mark Hudson (Investor Relations) Key Industry Insights Oncology Developments - Regeneron is positioning itself as a serious player in oncology, particularly with the development of Libtayo and its bispecific antibodies in hematologic malignancies [3][4] - The upcoming readout of the LAG-3 and PD-1 combination study is viewed as a significant milestone for the company [3] Clinical Trial Results - The LAG-3 antibody showed a high response rate of nearly 60% in PD-1 naive patients, leading to a phase three study to compare it against pembrolizumab (Keytruda) [4][5] - The study is designed to test two doses of fianlimab in combination with cemiplimab (Libtayo) versus pembrolizumab, with a focus on progression-free survival (PFS) [5][6] - The expected PFS for pembrolizumab is around 4-5 months, but Regeneron has set conservative expectations for their study [6][7] Market Potential - The global metastatic melanoma market is estimated to be around $4 billion to $5 billion [17] - Regeneron aims to leverage its existing leadership in non-melanoma skin cancers to expand into the melanoma market, which could significantly enhance its portfolio [17] Commercial Strategy - Libtayo has recently received approval for adjuvant treatment in cutaneous squamous cell carcinoma (CSCC), representing a potential market of approximately 10,000 patients in the U.S. [23][30] - The company is focusing on educating various specialties about the benefits of adjuvant treatment to ensure patients complete the full 48-week regimen [30][31] Pipeline and Future Prospects Ongoing Studies - Regeneron is conducting a phase two study in non-small cell lung cancer, with results expected in the first half of 2026 [20][22] - The company is also exploring neoadjuvant perioperative studies in both melanoma and lung cancer, indicating a data-rich period ahead [22] New Developments - Regeneron is advancing a range of new agents, including bispecific antibodies and PD-1 directed IL-2, which are showing early signs of efficacy [40][42] - The company is also launching Linvoseltamab in relapsed refractory multiple myeloma, with significant investment in clinical studies [44] Conclusion - Regeneron is optimistic about its future in oncology, with multiple studies and a strong pipeline that could lead to significant market opportunities. The focus on education and expanding treatment options is expected to enhance patient outcomes and drive growth in the coming years [45]

Core Insights - Phio Pharmaceuticals Corp. is set to present its INTASYL siRNA drug technology at the Advanced Therapies USA 2025 Congress, highlighting its potential in cancer treatment [1][2] - The INTASYL technology aims to down-regulate gene expression, with a specific focus on the PH-762 compound for treating cutaneous carcinomas [2][3] Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company that specializes in immuno-oncology therapeutics using its proprietary INTASYL® gene silencing technology [3] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [3] Presentation Details - The podium presentation titled "INTASYL® Synthesized siRNA Drug Technology" will take place on November 18, 2025, at 1:15 PM EDT in the Innovation Showcase at the Pennsylvania Convention Center [2] - Melissa Maxwell, M.S., will be the presenting author, emphasizing the significance of INTASYL technology in enhancing cancer treatment [2]

The average price target for NovaBridge Biosciences (NASDAQ:NBP) has decreased from $7.75 to $7.00 in the past month, indicating a slight decline in analyst optimism.NovaBridge's strategic partnerships and promising immuno-oncology agents in clinical trials highlight its potential in cancer treatment.Contrastingly, IMab (NASDAQ:IMAB) receives an upgrade to a Zacks Rank #2 (Buy), with a price target of $8, suggesting differing analyst views on these biotech companies.NovaBridge Biosciences (NASDAQ:NBP) is a ...

Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumors expected in late December 2025 or January 2026 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the C ...